New Delhi: India’s drug regulators are stepping up oversight of fast-growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market. Enhanced Monitoring and Safety Measures The move comes as the Indian Pharmacopoeia Commission (IPC), which functions under the Ministry of Health,.
